Lantus (Insulin Glargine)

Lantus (insulin glargine) is a basal insulin used to manage chronic hyperglycemia in diabetes.

• Type 1 diabetes mellitus: provides steady basal insulin to reduce fasting glucose and lower risk of ketoacidosis.
• Type 2 diabetes mellitus: complements oral agents or rapid‑acting insulin to maintain basal insulin levels and improve overall glycemic control.
• Pediatric type 1 diabetes mellitus (≥2 years): delivers consistent basal insulin, supporting growth and development while simplifying dosing schedules.

• Insulin glargine is a recombinant human insulin analog in which the amino‑acid sequence is modified to shift its isoelectric point, resulting in reduced solubility at physiological pH. After subcutaneous injection, it forms microprecipitates that slowly release insulin, allowing continuous activation of insulin receptors on muscle, adipose and hepatic cells. This promotes glucose uptake, inhibits hepatic gluconeogenesis, and sustains basal insulin activity for up to 24 hours.

Lantus may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: gradual increase in body weight associated with improved glycemic control.
• Lipodystrophy: localized thickening or lipoatrophy of subcutaneous tissue.
• Edema: mild peripheral swelling, often in the lower extremities.
• Headache: transient mild to moderate head pain.

Serious or Rare Side Effects

• Severe hypoglycemia: profound low glucose requiring assistance.
• Anaphylactic reaction: sudden onset of rash, swelling, airway compromise.
• Insulin allergy: systemic urticaria or angioedema.
• Insulin antibodies: may alter insulin action and cause unpredictable glucose levels.
• Diabetic ketoacidosis (rare): despite basal insulin, may occur if insulin absorption is impaired.
• Necrotizing fasciitis at injection site (extremely rare).

When using Lantus, several precautions should be observed to ensure safe and effective therapy.

• Dose titration: adjust dose gradually based on self‑monitored blood glucose and clinical response.
• Hypoglycemia risk: educate patients to recognize symptoms and have fast‑acting carbohydrate available.
• Illness management: monitor glucose more frequently and consider temporary dose adjustments during infection or stress.
• Renal/hepatic impairment: use lower initial doses and monitor closely for accumulation.
• Pregnancy and lactation: safety data are limited; prescribe only if benefits outweigh potential risks.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Lantus can interact with other medicines, influencing glucose levels or insulin action.

Major Interactions (Avoid)

• Sulfonylureas or meglitinides: combined use markedly increases risk of severe hypoglycemia.
• Pramlintide: concurrent administration may cause additive hypoglycemic effect.
• Systemic corticosteroids: can antagonize insulin action, leading to uncontrolled hyperglycemia.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms, requiring closer glucose monitoring.
• ACE inhibitors or ARBs: may enhance insulin sensitivity, potentially necessitating dose reduction.
• Thiazide diuretics: can raise blood glucose, warranting periodic assessment.
• Oral contraceptives: may alter insulin requirements during hormonal changes.